anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Almost 50% of U.S. veterans report they experience pain on a regular basis. This chronic pain often co-occurs with other disorders including post-traumatic stress disorder (PTSD), depression, anxiety and insomnia. A common approach to treating chronic pain is opioid analgesics, which are not always effective, and increasingly associated with abuse and misuse. Thus, there is an urgent need to develop readily available, safe, and practical complementary nonpharmacological approaches to manage chronic pain in U.S. veterans. Chronic pain is a multidimensional phenomenon, inter-related with many factors, including negative mood and poor sleep. The central circadian clock, in the suprachiasmatic nucleus in the hypothalamus, is well recognized to regulate both mood and sleep, and even small delays (shifts later) in circadian/sleep timing are associated with depression and disrupted sleep. These results suggests that later circadian/sleep timing may be a modifiable risk factor for pain. Thus, a self-administered morning bright light treatment at home may be a potentially efficacious adjunctive strategy for managing chronic pain. This R34 grant will develop a morning bright light treatment to help manage chronic pain and improve PTSD symptoms, depression, anxiety and sleep in U.S. veterans. Patients will have 7 baseline days at home, followed by a baseline pain sensitivity assessment and home circadian phase assessment (dim light melatonin onset). Following an instructional home visit, patients will then self-administer morning bright light treatment for 6 days, followed by reassessments of pain sensitivity and circadian phase. Assessments will be repeated after another 7 days of morning bright light treatment. Pain, mood and sleep (wrist actigraphy) will be assessed daily throughout baseline and treatment. Pain, mood and sleep will also be rated by veterans daily during a 1 month follow up after cessation of light treatment. This study will determine the feasibility, acceptability and efficacy of bright light treatment in a sample of U.S. veterans experiencing chronic low back pain.
Carcinogenesis

Two 2-year oral (gavage) carcinogenicity studies (one in Crl:B6C3F1 mice and one in Sprague-Dawley rats) were conducted with lubiprostone. In the 2-year carcinogenicity study in mice, lubiprostone doses of 25, 75, 200, and 500 mcg/kg/day (approximately 2, 6, 17, and 42 times the maximum recommended human dose, respectively, based on body surface area (mg/m2)) were used. In the 2-year rat carcinogenicity study, lubiprostone doses of 20, 100, and 400 mcg/kg/day (approximately 3, 17, and 68 times the maximum recommended human dose, respectively, based on body surface area (mg/m2)) were used. In the mouse carcinogenicity study, there was no significant increase in any tumor incidences. There was a significant increase in the incidence of interstitial cell adenoma of the testes in male rats at the 400 mcg/kg/day dose. In female rats, treatment with lubiprostone produced hepatocellular adenoma at the 400 mcg/kg/day dose.

Mutagenesis

Lubiprostone was not genotoxic in the in vitro Ames reverse mutation assay, the in vitro mouse lymphoma (L5178Y TK+/-) forward mutation assay, the in vitro Chinese hamster lung (CHL/IU) chromosomal aberration assay, and the in vivo mouse bone marrow micronucleus assay.

Impairment of Fertility

Lubiprostone, at oral doses of up to 1000 mcg/kg/day, had no effect on the fertility and reproductive function of male and female rats. However, the number of implantation sites and live embryos were significantly reduced in rats at the 1000 mcg/kg/day dose as compared to control. The number of dead or resorbed embryos in the 1000 mcg/kg/day group was higher compared to the control group, but was not statistically significant. The 1000 mcg/kg/day dose in rats is approximately 169 times the maximum recommended human dose of 48 mcg/day, based on body surface area (mg/m2).
An agent for the oxidative dyeing of keratinic fibres, comprising in a cosmetic carrier (A) at least one oxidation dye precursor of the structure (I) and/or one of its physiologically compatible salts: wherein R1 and R2, independently of one another, are hydrogen or a linear or branched C1-C10 alkyl group which can be substituted by one to ten hydroxyl groups, wherein R1 and R2 are not simultaneously hydrogen; (B) iminodisuccinic acid and/or at least one of its physiologically compatible salts, and (C) at least one oxidising agent other than atmospheric oxygen is provided. The dye precursor may have R1 as 2-hydroxylethyl, n-hexyl or n-heptyl and R2 as hydrogen. The oxidation dye precursor may be 1-hydroxylethyl-4,5-diaminopyrazole sulfate. Component (B) may comprise at least one sodium salt of iminodisuccinic acid, for example tetrasodium iminodisuccinate. The oxidising agent may be selected from hydrogen peroxide, sodium percarbonate, percarbonate and persalts, in particular peroxodisulfate salts and/or peroxomonosulfate salt and mixtures thereof. Multi-component packing units (kits-of-parts) for oxidative dyeing of keratinic fibres comprising the components (A), (B) and (C) are provided. A method for the oxidative hair dyeing of keratinic fibres with the agent or kit-of parts is provided.
Desired skin colour is a major unmet consumer need in Asia. Consumers particularly desire even skin colour, absence of age spots (solar lentigines) and lighter overall skin tone. One solution is to use biological actives that reduce the activity of melanocytes in skin. These cells, present in the basal layer of the epidermis, make the darkly coloured pigment melanin and export it in small export vesicles called melanosomes to the neighbouring keratinocytes. It is well described in the literature that compounds which reduce melanin synthesis when topically applied to the skin will reduce skin darkness over time. This invention relates to a composition comprising a synergistic combination of ketoconazole and sulforaphane for use in skin lightening. This invention is based on the fact that a combination of ketoconazole and sulforaphane has been found tosynergistically inhibit pigment production in B16 monolayer cultures. Thus the composition, when applied topically or imbibed over an appropriate length of time in-vivo, would be expected to cause skin lightening, or to reduce blemishes and/or hyperpigmented spots and/or solar lentigines leading to an improvement in skin tone and evenness.
Infusion 100 mL of normal saline with constant speed in 20 minutes. Administration only once.
Acute Lymphoblastic Leukemia (ALL) is a heterogeneous blood cancer characterized by the uncontrolled growth of immature lymphoid cells due to dysregulated signaling pathways. It is the most common pediatric cancer, with high cure rates in children, but significantly lower survival rates in adults. Current theranostic strategies, including chemotherapy, immunotherapy, and nanomedicine, aim to improve detection and treatment precision but are limited by side effects, drug resistance, high costs, and stability issues. Notably, extracellular vesicles (EVs) offer a promising alternative, addressing these limitations through their natural biocompatibility and targeted delivery capabilities. EVs play a dual role in ALL: they contribute to leukemia progression by promoting tumor growth, immune suppression, and drug resistance via the transfer of oncogenic molecules, while also serving as valuable non-invasive biomarkers due to their specific miRNA and protein content. Their ability to deliver therapeutic agents directly to leukemic cells, combined with their stability and low immunogenicity, makes EVs a compelling tool for improving ALL treatments. Indeed, by targeting the molecular pathways influenced by EVs or leveraging them for drug delivery, innovative therapeutic strategies can be developed to enhance treatment outcomes and reduce side effects. Thus, EVs represent a promising frontier for advancing theranostic strategies in ALL, offering new opportunities to improve diagnosis and treatment while overcoming the limitations of traditional therapies. This review will explore the dual roles of EVs in ALL, addressing their contributions to disease progression and their potential as therapeutic agents and biomarkers for early diagnosis and targeted therapies.
This group will receive transcutaneous vagal nerve stimulation, initially. Participants will be randomized between the two arms of the crossover sessions (initial tVNS vs. initial Sham). Behavioral portions of the testing will then be carried out twice, with at least 72 hours between sessions (to avoid carryover effects).
Background and Purpose: Fall prevention through exercise is an ongoing goal of researchers and clinicians. This study compared the effects of aquatic exercise (AE), land exercise (LE) and no exercise (NE) on fall risk factors. Subjects: Seventy-three women, 60 or older, with osteoporosis (OP). Method: Randomized clinical trial comparing balance, posture, strength, mobility, function, falls, and quality of life. Results: Significant differences (p\<0.05) were found for participants' ratings of global change (AE and LE \> NE), tandem balance (AE \> LE) and function (LE \> AE). Joint pain and falls occurred more often during LE. Discussion and Conclusion: Participants experienced significant global improvement with both AE and LE. Less joint pain, reduced falls and improved balance were found in AE, however LE was more effective in improving functional ability at home. Clinicians should consider the individual's specific impairments and risk factors when recommending exercise programs on land or in water.
ABSTRACT OF THE DISCLOSURE A preparation is provided herein which may be used for diagnostic purposes for the detection of chlamydial infections.  The preparation comprises a Re-lipopolysaccharide complexed to a carrier molecule to enhance immunological response isolated from the Re-mutants of Gram negative bacteria or an anti body to a Re-lipopolysaccharide complexed to a carrier molecule to enhance immunological response, the anti-Re-lipopolysaccharide complex antibody being produced by immunizing animals with Re-lipopolysaccharide complexed to a carrier molecule to enhance immunological response. The anti-Re-lipopoly-saccharide complex antibody is capable of cross-reacting with chlamydial group-specific antigens.  Advantageously, the Re-mutants of Gram negative bacteria are Salmonella minnes ta mR595, deposit No. SH 320, Public Health Institute, Helsinki, Finland, Salmonella typhimurium Re, deposit No. SL 1102, Public Health Institute, Helsinki, Finland, Escherichia coli D21f2, deposit No. EH237, Public Health Institute, Helsinki, Finland or Proteus mirabilis R45, deposit No. EH 193, Public Health Institute, Helsinki, Finland.  The lipopolysaccharide preparation is used in the production of group-specific antibodies to chlamydial for diagnostic purposes or for the demonstration of antibodies to chlamydial group antigne in specimens.  Thus, the product can be used for the demonstration of chlamydial infections, for example in various serological and immunolgical methods, e.g. the counterimmunoelectrophoresis method, passive hemagglutination method, and the HIG, EIA, FIA, RIA and latex agglutinization methods.
If clinically advisable, patients receiving MS CONTIN® or their caregivers should be given the following information by the physician, nurse, or pharmacist:

  1. Patients should be advised that MS CONTIN Tablets contain morphine and should be taken only as directed.
  2. Patients should be advised that MS CONTIN Tablets were designed to work properly only if swallowed whole. MS CONTIN Tablets will release all of their morphine if split, divided, broken, chewed, dissolved, or crushed resulting in the risk of a fatal overdose.
  3. Patients should be advised not to change the dose of MS CONTIN without consulting their physician.
  4. Patients should be advised to report episodes of breakthrough pain and adverse experiences occurring during therapy. Individualization of dosage is essential to make optimal use of this medication.
  5. MS CONTIN may impair mental and/or physical ability required for the performance of potentially hazardous tasks (e.g., driving, operating machinery). Patients started on MS CONTIN or whose dose has been changed should refrain from dangerous activity until it is established that they are not adversely affected.
  6. MS CONTIN should not be taken with alcohol or other CNS depressants (sleep aids, tranquilizers) except by the orders of the prescribing physician because dangerous additive effects may occur resulting in serious injury or death.
  7. Women of childbearing potential who become or are planning to become pregnant should be advised to consult their physician regarding the effects of analgesics and other drug use during pregnancy on themselves and their unborn child.
  8. Patients should be advised that if they have been receiving treatment with MS CONTIN for more than a few weeks and cessation of therapy is indicated, it may be appropriate to taper the MS CONTIN dose, rather than abruptly discontinue it, due to the risk of precipitating withdrawal symptoms. Their physician can provide a dose schedule to accomplish a gradual discontinuation of the medication.
  9. MS CONTIN® 100 mg and 200 mg Tablets are for use only in opioid-tolerant patients requiring daily morphine equivalent dosages of 200 mg or more for the 100 mg tablet and 400 mg or more for the 200 mg tablet. Special care must be taken to avoid accidental ingestion or the use by individuals (including children) other than the patient for whom it was originally prescribed, as such unsupervised use may have severe, even fatal, consequences.
  10. Patients should be advised that MS CONTIN® is a potential drug of abuse. They should protect it from theft, and it should never be given to anyone other than the individual for whom it was prescribed.
  11. Patients should be advised that they may pass empty matrix "ghosts" (tablets) via colostomy or in the stool, and that this is of no concern since the active medication has already been absorbed.
  12. Patients should be instructed to keep MS CONTIN in a secure place out of the reach of children. When MS CONTIN is no longer needed, the unused tablets should be destroyed by flushing down the toilet.
The invention discloses an external medicament composition for treating arthritis. The external medicament composition is characterized by comprising the following raw materials in parts by weight: 2 to 5 parts of spiderflower seed, 2 to 4 parts of capsicum annuum and 8 to 12 parts of dimethyl sulfoxide. The external medicament composition is prepared according to the following steps of: grinding the spiderflower seed and the capsicum annuum into fine powder, adding the dimethyl sulfoxide and mixing uniformly. The prepared external medicament composition, namely a paste is put into a plastic bag before being used. When the paste is used, the plastic bag is cut off from the periphery to ensure that the medicament in the plastic bag is divided into two parts paved on two plastic films which are formed by cutting the plastic bag, and each plastic film is pasted to the affected part and fixed by adhesive tapes for 3 to 4 hours every time. The affected part can not be washed with water in 5 to 6 days, and the medicament composition can not be used for the second time in 10 to 15 days. The medicament composition is externally used, is convenient to use and has a good treatment effect.
The invention discloses kind Metalnikowin antibacterial peptide and an application thereof, belong to technical field of molecular biology. Class Metalnikowin antibacterial peptide is made up of 23 amino acid, is its amino acid sequence as SEQ? ID? shown in NO.1, molecular size range is 2742.17Da. This antibacterial peptide can suppress the growth of the bacteriums such as chicken colibacillosis, swine escherichia coli, salmonella, staphylococcus aureus and Pasteurella, compared with the antibiotic such as penicillin, streptomysin, brizolina, azithromycin, fungistatic effect is relatively better, with Metalnikowin? I, Metalnikowin? IIA, Metalnikowin? the Metalnikowin antibacterial peptide of the routines such as IIB is compared, and has stronger bacteriostatic activity. This antibacterial peptide is 312.5 μ g/mL to the minimal inhibitory concentration of salmonella, and good thermal stability, can also promote chick weight gains, in antibiotic property drug development and animal husbandry development, has a good application prospect.
PURPOSE:To provide the titled promoting agent composed of a metallic salt of oxalic acid having a specific ionic radius, having XII factor activating capability, capable of remarkably shortening the time necessary for the coagulation of blood, and having extremely stable promoting effect. CONSTITUTION:The objective blood coagulating agent is composed of a metallic salt of oxalic acid, wherein said metallic ion has a valency of >=2 (e.g. Cu<2+>, Co<2+>, Fe<2+>, Ni<2+>, Mg<2+>, Ce<6+>, etc.) and has an ionic radius of 0.50-1.04Angstrom . The concentration of the oxalate in blood is at least 1X10<-10>g/ml (blood). The oxalate may be added to the blood in the form of powder or after dispersing in a solvent, etc., however, it is preferable to support the oxalate on a carrier having large specific surface area, and add the carrier to the blood in a container for the examination of blood. The agent can be used also for the stopping of bleeding of a wound.
Quetiapine and norquetiapine have affinity for multiple neurotransmitter receptors including dopamine D1 and D2, serotonin 5HT1A and 5HT2A, histamine H1, muscarinic M1 and adrenergic α1b and α2 receptors. Quetiapine differs from norquetiapine in having no appreciable affinity for muscarinic M1 receptors whereas norquetiapine has high affinity. Quetiapine and norquetiapine lack appreciable affinity for benzodiazepine receptors.

  


Effect on QT Interval

In clinical trials quetiapine was not associated with a persistent increase in QT intervals. However, the QT effect was not systematically evaluated in a thorough QT study. In post marketing experience there were cases reported of QT prolongation in patients who overdosed on quetiapine [see Overdosage (10.1)], in patients with concomitant illness, and in patients taking medicines known to cause electrolyte imbalance or increase QT interval.
The present invention relates to compounds of quinolyl organic germanium ester having the following Formula 1 and the synthesis methods thereof. R 1  and R 2  are defined in the specification. Organic germanium acyl chloride and 8-hydroxylquinoline were used as the starting raw materials. Displacement reaction was carried out at 0-40° C., followed by hydrolysis reaction and then by changing the solvent, water soluble quinolyl organic germanium ester was finally obtained. The quinolyl organic germanium ester possesses better water solubility and fat solubility. Due to the existence of both drug active group (organic germanium part) and drug recognizing group (quinoline part) in the structure of the quinolyl organic germanium ester, the compound is expected to develop a novel kind of anti-tumor drug.
BACKGROUND/OBJECTIVES: The discrepancy between the current perceived body image (BI) and beauty ideals leads to dissatisfaction, which is believed to be common among adolescents. This study aimed to investigate the stability in BI perceptions and dissatisfaction during early adolescence. Another aim was to highlight differences in dissatisfaction according to Body Mass Index (BMI) and inconsistencies in weight status perception.
METHODS: Two hundred and nine participants (mean age at first survey: 11.33 ± 0.38 years) were enrolled in this longitudinal study with three years of follow-up. Data on size and BI perceptions were collected through individual interviews. Stature and weight were directly measured.
RESULTS: Findings indicated significant changes over three years in anthropometric traits but not in weight status prevalence or BI perception and dissatisfaction, except for the ideal figure in males and weight control in females. The results also indicated a significant difference in BI perception and dissatisfaction by BMI categories. Self-reported body measurements were found to be unreliable with a weak-to-moderate agreement between self-perceived and actual weight status.
CONCLUSIONS: BI perception appears quite stable across the three years considered. Dissatisfaction is similar in both genders, although a tendency toward different gender aesthetic ideals is already appreciable in early adolescence. We suggest that the lower frequency of normal-weight adolescents compared with peers in previous studies is attributable to the effects of the recent pandemic. Given the growing dissatisfaction with increasing BMI and misinterpretations of weight status, school actions to promote a healthy lifestyle and positive BI should be undertaken.
For short-term therapy of transient functional cardiovascular symptoms, borderline active dosage forms of beta blockers are used which produce in the body only the borderline active concentrations of active ingredient which produce no significant changes in the physiological values in the cardiovascular system under resting conditions for the respective specific beta blocker used and significantly reduce adrenergically induced transient stimulation effects. Oral, transdermal, or topical dosage forms are particularly advantageous. A differentiated therapy of functional symptoms which does not exist with the customary dosage forms of beta blockers designed for long-term therapies is possible. Both the quality of life and the risk-benefit ratio of the beta blockers are improved. The duration of the therapy also does not have to be extended beyond the symptomatically required scale since no rebound danger exists after withdrawal. As an additional and now indication, this also permits the short-term use for the primary therapy of sleep disturbances, within the framework of vegetative syndromes, in particular, within the framework of postmenopausal symptoms.